# GBA1

## Overview
The GBA1 gene encodes the enzyme glucosylceramidase beta 1 (GCase), a lysosomal hydrolase crucial for the breakdown of glucosylceramides into glucose and ceramide. This enzyme is categorized as a lysosomal enzyme and plays a pivotal role in lipid metabolism and cellular homeostasis. GCase is synthesized in the endoplasmic reticulum and transported to the lysosome, where it becomes active in the acidic environment, facilitated by the lysosomal integral membrane protein-2 (LIMP2) (Behl2021Crosstalks). Mutations in the GBA1 gene are associated with Gaucher's disease, a lysosomal storage disorder, and are a significant genetic risk factor for Parkinson's disease and other synucleinopathies (Avenali2020Glucocerebrosidase; Granek2023GBA1). The enzyme's interaction with α-synuclein, a protein implicated in Parkinson's disease, further underscores its clinical significance (Yap2013Membranebound).

## Structure
The GBA1 gene encodes the enzyme glucosylceramidase beta 1 (GCase), which is involved in the hydrolysis of glucosylceramides. The mature GCase protein consists of 497 amino acids and is structured into three main domains. Domain I is an antiparallel β-sheet, Domain II is a (β/α)8 triosephosphate isomerase (TIM) barrel that contains the active site, and Domain III is an eight-stranded β-barrel resembling an immunoglobulin fold (Granek2023GBA1; Behl2021Crosstalks). The enzyme undergoes post-translational modifications, including glycosylation, which is critical for its function, with N19 being a significant glycosylation site (Liou2019Combination).

The GCase protein is synthesized in the endoplasmic reticulum and transported to the lysosome, where it becomes active in the acidic environment. This transport is facilitated by the lysosomal integral membrane protein-2 (LIMP2) and is independent of the mannose-6-phosphate pathway (Behl2021Crosstalks). The enzyme's structure is highly homologous between humans and mice, with 85% amino acid identity (Liou2019Combination). Mutations in the GBA1 gene can lead to reduced GCase activity, contributing to lysosomal dysfunction and α-synucleinopathies (Granek2023GBA1).

## Function
The GBA1 gene encodes the enzyme glucocerebrosidase, which plays a critical role in the lysosomal breakdown of glucocerebroside into glucose and ceramide. This enzymatic activity is essential for maintaining lipid metabolism and cellular homeostasis. In healthy human cells, glucocerebrosidase prevents the accumulation of glucosylceramide and glucosylsphingosine, substrates that, if not properly degraded, can lead to cellular dysfunction (Liu2012Gaucher).

The enzyme is active within lysosomes, where it facilitates the degradation of glucosylceramide, a process crucial for normal cellular function, particularly in the mononuclear phagocyte lineage. This activity is vital for preventing the buildup of lipids that can disrupt cellular processes and lead to disease (Liu2012Gaucher). The proper function of glucocerebrosidase is also linked to immune regulation, as its deficiency can result in immune cell aberrations, affecting T-cell maturation, B-cell recruitment, and cytokine production (Liu2012Gaucher).

In the context of Gaucher disease, mutations in the GBA1 gene lead to a deficiency in glucocerebrosidase activity, resulting in the accumulation of its substrates and causing various clinical manifestations, including hepatosplenomegaly and bone marrow infiltration (Liu2012Gaucher).

## Clinical Significance
Mutations in the GBA1 gene, which encodes the enzyme glucocerebrosidase, are significantly associated with several neurodegenerative diseases, particularly Parkinson's disease (PD) and Gaucher's disease (GD). GBA1 mutations are a major genetic risk factor for PD, increasing the risk by 5 to 30 times compared to non-carriers. These mutations lead to reduced enzymatic activity of glucocerebrosidase, resulting in impaired lysosomal function and the accumulation of pathological alpha-synuclein, a hallmark of PD. This dysfunction can also cause mitochondrial impairment, endoplasmic reticulum stress, and neuroinflammation (Avenali2020Glucocerebrosidase; Granek2023GBA1; Zhang2024Clinical).

Gaucher's disease, a lysosomal storage disorder, is caused by biallelic mutations in GBA1, leading to the accumulation of glucosylceramide. GD is classified into different types based on neurological involvement, with type 1 being non-neuronopathic and types 2 and 3 being neuronopathic. Common mutations associated with GD include N370S and L444P, which lead to reduced glucocerebrosidase activity through mechanisms such as protein misfolding and endoplasmic reticulum stress (Granek2023GBA1; Zhang2024Clinical).

GBA1 mutations are also linked to other synucleinopathies, such as dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD), where they contribute to earlier onset and more severe symptoms (Lerche2019Parkinson’s; Behl2021Crosstalks).

## Interactions
The GBA1 gene encodes the enzyme glucocerebrosidase (GCase), which is involved in several critical protein interactions. One significant interaction is with α-synuclein, a protein associated with Parkinson's disease. Membrane-bound α-synuclein interacts with GCase, inhibiting its enzymatic activity. This interaction is site-specific and occurs under lysosomal conditions, with α-synuclein adopting an open horseshoe helix conformation when bound to the membrane (Yap2013Membranebound). The C-terminal region of α-synuclein is the primary site of interaction, and this interaction is characterized by energy transfer from tryptophan residues in GCase to dansyl-labeled α-synuclein (Yap2013Membranebound).

GCase also interacts with LIMP-2, a lysosomal integral membrane protein that acts as a receptor for its mannose-6-phosphate-independent targeting to lysosomes. This interaction is crucial for the proper lysosomal localization and activity of GCase. The coiled-coil domain within the lumenal domain of LIMP-2 is essential for binding to GCase, and this interaction is pH-sensitive, occurring at neutral pH in the endoplasmic reticulum and dissociating at the acidic pH of lysosomes (Reczek2007LIMP2).


## References


[1. (Behl2021Crosstalks) Tapan Behl, Gagandeep Kaur, Ovidiu Fratila, Camelia Buhas, Claudia Teodora Judea-Pusta, Nicoleta Negrut, Cristiana Bustea, and Simona Bungau. Cross-talks among gba mutations, glucocerebrosidase, and α-synuclein in gba-associated parkinson’s disease and their targeted therapeutic approaches: a comprehensive review. Translational Neurodegeneration, January 2021. URL: http://dx.doi.org/10.1186/S40035-020-00226-X, doi:10.1186/s40035-020-00226-x. This article has 68 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1186/S40035-020-00226-X)

[2. (Lerche2019Parkinson’s) Stefanie Lerche, Isabel Wurster, Benjamin Roeben, Milan Zimmermann, Benjamin Riebenbauer, Christian Deuschle, Ann‐Kathrin Hauser, Claudia Schulte, Daniela Berg, Walter Maetzler, Katharina Waniek, Ingolf Lachmann, Inga Liepelt‐Scarfone, Thomas Gasser, and Kathrin Brockmann. Parkinson’s disease: glucocerebrosidase 1 mutation severity is associated with csf alpha‐synuclein profiles. Movement Disorders, 35(3):495–499, October 2019. URL: http://dx.doi.org/10.1002/mds.27884, doi:10.1002/mds.27884. This article has 34 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1002/mds.27884)

[3. (Avenali2020Glucocerebrosidase) Micol Avenali, Fabio Blandini, and Silvia Cerri. Glucocerebrosidase defects as a major risk factor for parkinson’s disease. Frontiers in Aging Neuroscience, April 2020. URL: http://dx.doi.org/10.3389/fnagi.2020.00097, doi:10.3389/fnagi.2020.00097. This article has 79 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fnagi.2020.00097)

[4. (Granek2023GBA1) Zuzanna Granek, Julia Barczuk, Natalia Siwecka, Wioletta Rozpędek-Kamińska, Ewa Kucharska, and Ireneusz Majsterek. Gba1 gene mutations in α-synucleinopathies—molecular mechanisms underlying pathology and their clinical significance. International Journal of Molecular Sciences, 24(3):2044, January 2023. URL: http://dx.doi.org/10.3390/ijms24032044, doi:10.3390/ijms24032044. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms24032044)

[5. (Zhang2024Clinical) Xuxiang Zhang, Heng Wu, Beisha Tang, and Jifeng Guo. Clinical, mechanistic, biomarker, and therapeutic advances in gba1-associated parkinson’s disease. Translational Neurodegeneration, September 2024. URL: http://dx.doi.org/10.1186/s40035-024-00437-6, doi:10.1186/s40035-024-00437-6. This article has 0 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1186/s40035-024-00437-6)

[6. (Liou2019Combination) Benjamin Liou, Wujuan Zhang, Venette Fannin, Brian Quinn, Huimin Ran, Kui Xu, Kenneth D. R. Setchell, David Witte, Gregory A. Grabowski, and Ying Sun. Combination of acid β-glucosidase mutation and saposin c deficiency in mice reveals gba1 mutation dependent and tissue-specific disease phenotype. Scientific Reports, April 2019. URL: http://dx.doi.org/10.1038/s41598-019-41914-7, doi:10.1038/s41598-019-41914-7. This article has 17 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-019-41914-7)

[7. (Liu2012Gaucher) Jun Liu, Stephanie Halene, Mei Yang, Jameel Iqbal, Ruhua Yang, Wajahat Z. Mehal, Wei-Lien Chuang, Dhanpat Jain, Tony Yuen, Li Sun, Mone Zaidi, and Pramod K. Mistry. Gaucher disease genegbafunctions in immune regulation. Proceedings of the National Academy of Sciences, 109(25):10018–10023, June 2012. URL: http://dx.doi.org/10.1073/pnas.1200941109, doi:10.1073/pnas.1200941109. This article has 62 citations.](https://doi.org/10.1073/pnas.1200941109)

[8. (Reczek2007LIMP2) David Reczek, Michael Schwake, Jenny Schröder, Heather Hughes, Judith Blanz, Xiaoying Jin, William Brondyk, Scott Van Patten, Tim Edmunds, and Paul Saftig. Limp-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of β-glucocerebrosidase. Cell, 131(4):770–783, November 2007. URL: http://dx.doi.org/10.1016/j.cell.2007.10.018, doi:10.1016/j.cell.2007.10.018. This article has 420 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.cell.2007.10.018)

[9. (Yap2013Membranebound) Thai Leong Yap, Arash Velayati, Ellen Sidransky, and Jennifer C. Lee. Membrane-bound α-synuclein interacts with glucocerebrosidase and inhibits enzyme activity. Molecular Genetics and Metabolism, 108(1):56–64, January 2013. URL: http://dx.doi.org/10.1016/j.ymgme.2012.11.010, doi:10.1016/j.ymgme.2012.11.010. This article has 90 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ymgme.2012.11.010)